Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00630-17. doi: 10.1128/AAC.00630-17. Print 2017 Dec.

2.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Int J Antimicrob Agents. 2017 Jan;49(1):25-30. doi: 10.1016/j.ijantimicag.2016.07.015. Epub 2016 Sep 1.

PMID:
27931793
3.

Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.

VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3891-6. doi: 10.1128/AAC.02943-15. Print 2016 Jul.

4.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

5.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.

6.

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31. doi: 10.1128/AAC.02310-13. Epub 2014 Jul 28.

7.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.

8.

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.

Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17.

9.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.

11.

Retrospective review of the use of daptomycin for diabetic foot infections.

Johnson K, Lamp KC, Friedrich LV.

J Wound Care. 2009 Sep;18(9):396-400.

PMID:
19789477
12.

Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).

Mohr JF, Friedrich LV, Yankelev S, Lamp KC.

Int J Antimicrob Agents. 2009 Jun;33(6):543-8. doi: 10.1016/j.ijantimicag.2008.12.007. Epub 2009 Feb 6.

PMID:
19201165
13.

Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.

Forrest GN, Donovan BJ, Lamp KC, Friedrich LV.

Ann Pharmacother. 2008 Feb;42(2):213-7. doi: 10.1345/aph.1K535. Epub 2008 Jan 22.

PMID:
18212253
14.

Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.

Owens RC Jr, Lamp KC, Friedrich LV, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S6-12.

PMID:
17904950
15.

Cubicin Outcomes Registry and Experience (CORE) methodology.

Rolston KV, Segreti J, Lamp KC, Friedrich LV.

Am J Med. 2007 Oct;120(10 Suppl 1):S4-5.

PMID:
17904949
16.

Daptomycin in the treatment of bacteremia.

Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S21-7.

PMID:
17904947
17.

Clinical experience with daptomycin for the treatment of patients with osteomyelitis.

Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R.

Am J Med. 2007 Oct;120(10 Suppl 1):S13-20.

PMID:
17904946
18.

Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study.

Holtom PD, Zalavras CG, Lamp KC, Park N, Friedrich LV.

Clin Orthop Relat Res. 2007 Aug;461:35-9.

PMID:
17549028
19.

Fatal hypoglycemia associated with levofloxacin.

Friedrich LV, Dougherty R.

Pharmacotherapy. 2004 Dec;24(12):1807-12.

PMID:
15585448
20.

Assessment of differences in antimicrobial effect determined with two in vitro pharmacodynamic models: impact of surface area to volume ratio.

White RL, Bonapace CR, Friedrich LV, Rybak MJ, Cappelletty DM, Mercier RC, Houlihan HH, Aeschlimann JR, Bosso JA.

Pharmacotherapy. 2003 May;23(5):603-8.

PMID:
12741434
21.

Comparison of methods of interpretation of checkerboard synergy testing.

Bonapace CR, Bosso JA, Friedrich LV, White RL.

Diagn Microbiol Infect Dis. 2002 Dec;44(4):363-6.

PMID:
12543542
22.

Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection.

Bonapace CR, Friedrich LV, Bosso JA, White RL.

Antimicrob Agents Chemother. 2002 Nov;46(11):3574-9.

23.

Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.

White RL, Enzweiler KA, Friedrich LV, Wagner D, Hoban D, Bosso JA.

Diagn Microbiol Infect Dis. 2002 Jul;43(3):207-17.

PMID:
12106954
24.

Effect of serum from different patient populations on the serum bactericidal test.

Kays MB, White RL, Friedrich LV.

J Antimicrob Chemother. 2001 Sep;48(3):417-20.

PMID:
11533009
25.

Effect of removal of duplicate isolates on cumulative susceptibility reports.

White RL, Friedrich LV, Burgess DS, Brown EW, Scott LE.

Diagn Microbiol Infect Dis. 2001 Apr;39(4):251-6.

PMID:
11404069
26.

Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis.

White RL, Friedrich LV, Manduru M, Mihm LB, Bosso JA.

Diagn Microbiol Infect Dis. 2001 Jan;39(1):39-47.

PMID:
11173190
27.

Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods.

Bonapace CR, White RL, Friedrich LV, Bosso JA.

Diagn Microbiol Infect Dis. 2000 Sep;38(1):43-50.

PMID:
11025183
28.

Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient-care areas.

White RL, Friedrich LV, Mihm LB, Bosso JA.

Clin Infect Dis. 2000 Jul;31(1):16-23. Epub 2000 Jul 14.

PMID:
10913390
29.

Pharmacokinetics of cefepime in patients with thermal burn injury.

Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA.

Antimicrob Agents Chemother. 1999 Dec;43(12):2848-54.

30.

Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes.

Friedrich LV, White RL, Bosso JA.

Clin Infect Dis. 1999 May;28(5):1017-24.

PMID:
10452628
31.
32.

In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA.

Antimicrob Agents Chemother. 1997 Sep;41(9):2053-6.

33.

The costs of burn care: an analysis with an emphasis on the use of parenteral antimicrobials.

Nicolau DP, White RL, Friedrich LV, Kays MB.

J Burn Care Rehabil. 1994 May-Jun;15(3):244-50.

PMID:
8056815
34.

Drug degradation during HPLC analysis of aztreonam: effect on pharmacokinetic parameter estimation.

Friedrich LV, White RL, Kays MB, Burgess DS.

Ann Pharmacother. 1994 Apr;28(4):444-6.

PMID:
8038462
35.
36.

Pharmacoeconomic evaluation of treatment of penetrating abdominal trauma.

Friedrich LV, White RL, Kays MB, Burgess DS.

Am J Hosp Pharm. 1992 Mar;49(3):590-4.

PMID:
1598932
37.

Evaluation of cephalosporins/cephamycins with antianaerobic activity by integrating microbiologic and pharmacokinetic properties.

Kays MB, White RL, Friedrich LV, Del Bene VE.

Clin Ther. 1991 Sep-Oct;13(5):596-605.

PMID:
1799917
38.
39.

Aztreonam pharmacokinetics in burn patients.

Friedrich LV, White RL, Kays MB, Brundage DM, Yarbrough D 3rd.

Antimicrob Agents Chemother. 1991 Jan;35(1):57-61.

40.

Antibiotic prophylaxis and tourniquet inflation in total knee arthroplasty.

Friedman RJ, Friedrich LV, White RL, Kays MB, Brundage DM, Graham J.

Clin Orthop Relat Res. 1990 Nov;(260):17-23.

PMID:
2121406
41.

Effects of supraphysiologic temperature and broth dilution on serum protein binding.

White RL, Kays MB, Armstrong TA, Friedrich LV.

Antimicrob Agents Chemother. 1990 Jun;34(6):1257-8.

42.

The effect of tourniquet inflation on cefazolin tissue penetration during total knee arthroplasty.

Friedrich LV, White RL, Brundage DM, Kays MB, Friedman RJ.

Pharmacotherapy. 1990;10(6):373-7.

PMID:
2287555
43.

Pharmacodynamics of trimethoprim-sulfamethoxazole in Listeria meningitis: a case report.

Friedrich LV, White RL, Reboli AC.

Pharmacotherapy. 1990;10(4):301-4.

PMID:
2117750
44.

Ein Fall von Anguillula intestinalis.

FRIEDRICH LV.

Gastroenterologia. 1949;74(3):150-6. Undetermined Language. No abstract available.

PMID:
18117068
45.

Der Flatz der Gastroskopie in der Magendiagnostik.

FRIEDRICH LV.

Gastroenterologia. 1947;72(3-4):216-23. Undetermined Language. No abstract available.

PMID:
20268348

Supplemental Content

Loading ...
Support Center